Author(s): Christian Lampl | Christine Schweiger
Journal: European Neurological Journal
ISSN 2041-8000
Volume: 2;
Issue: 1;
Start page: 83;
Date: 2010;
VIEW PDF
DOWNLOAD PDF 
Original page
Keywords: Migraine | antidepressants | prophylactic treatment | SSRIs | SNRIs
ABSTRACT
The objectives of this review are to provide a comprehensive critical analysis of published reports of randomized controlled trials of antidepressants for reducing headache burden among adults with migraine, and to determine whether efficacy varies according to important patient characteristics, such as coexisting depression. The mechanism whereby amitriptyline and other antidepressants produce their analgesic effects is unknown, but the blockade of serotonin and norepinephrine re-uptake has been hypothesized to play a pivotal role. Concerning amitriptyline, there is some evidence that this tricyclic antidepressant may be beneficial in the prophylaxis of migraine in some patients. For selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), beneficial effects are equivalent to those seen in the placebo group within 2 months of therapy. To conclude, there is limited evidence for a clinical superiority of amitriptyline and SSRIs over other treatments with ß-blockers, anticonvulsants, or calcium channel blockers in preventing migraine. Antidepressants in migraine should be considered if other first- or second-line drugs have not reduced the number of monthly attacks or if concomitant depression exists. Therefore, antidepressants are second- or (even) third-line prophylactic agents in patients with migraine alone.
Journal: European Neurological Journal
ISSN 2041-8000
Volume: 2;
Issue: 1;
Start page: 83;
Date: 2010;
VIEW PDF
DOWNLOAD PDF Original pageKeywords: Migraine | antidepressants | prophylactic treatment | SSRIs | SNRIs
ABSTRACT
The objectives of this review are to provide a comprehensive critical analysis of published reports of randomized controlled trials of antidepressants for reducing headache burden among adults with migraine, and to determine whether efficacy varies according to important patient characteristics, such as coexisting depression. The mechanism whereby amitriptyline and other antidepressants produce their analgesic effects is unknown, but the blockade of serotonin and norepinephrine re-uptake has been hypothesized to play a pivotal role. Concerning amitriptyline, there is some evidence that this tricyclic antidepressant may be beneficial in the prophylaxis of migraine in some patients. For selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), beneficial effects are equivalent to those seen in the placebo group within 2 months of therapy. To conclude, there is limited evidence for a clinical superiority of amitriptyline and SSRIs over other treatments with ß-blockers, anticonvulsants, or calcium channel blockers in preventing migraine. Antidepressants in migraine should be considered if other first- or second-line drugs have not reduced the number of monthly attacks or if concomitant depression exists. Therefore, antidepressants are second- or (even) third-line prophylactic agents in patients with migraine alone.
